精神分裂症缺乏精准的诊断（包括早期诊断）与预测药物疗效的生物学标记物，无法实现预防治疗。已有的大多数生物学标记物研究因设计不够完善使结果难以被重复。本课题以前期的生物学标记物研究为基础，精选优化出表观遗传学、脑影像学、神经免疫等重要生物学标记物，在首发患者、前驱期超高危人群及未患病同胞的不同疾病阶段研究早期诊断价值，并观察治疗中生物学标记物的变化是否为治疗靶点并具有预测疗效价值，为精神分裂症的早期诊断与预防干预提供有效手段，揭示精神分裂症的生物学病理机制。

Lack of reliable biomarkers for early-detection and measuring treatment effect has made it difficult to conduct effective intervention on patients with schizophrenia. While individual studies have discovered some biomarkers, most of them have limitations in study design, and results are inconsistent. Based on findings from our previous studies and utilizing advanced study designs including multiple control groups, follow-upping prodromal individuals, pharmacological interventions, this study aims to systematically evaluate potential biomarkers of brain imaging, epigenetics and neuroimmunology in patients with schizophrenia in larger samples. In addition, the proposed study will also examine the genetic variants that may be associated with biomarkers and that may affect the gene expression in postmortem of human brains. We expect that the study will find potential biomarkers that can be used for early-detection of schizophrenia and evaluating the treatment response to antipsychotics; and finally may reveal potential novel therapeutic target for treatment and understanding the biological mechanism of schizophrenia.